Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 292.12 Billion KRW | 6.6% |
| 2022 | 274.03 Billion KRW | 9.58% |
| 2021 | 250.07 Billion KRW | 6.34% |
| 2020 | 235.16 Billion KRW | -2.79% |
| 2019 | 241.92 Billion KRW | -6.96% |
| 2018 | 260.01 Billion KRW | 6.01% |
| 2017 | 245.27 Billion KRW | 2.49% |
| 2016 | 239.31 Billion KRW | 10.53% |
| 2015 | 216.51 Billion KRW | 7.55% |
| 2014 | 201.3 Billion KRW | 4.84% |
| 2013 | 192 Billion KRW | 3.4% |
| 2012 | 185.7 Billion KRW | -7.96% |
| 2011 | 201.75 Billion KRW | 0.67% |
| 2010 | 200.41 Billion KRW | 21.18% |
| 2009 | 165.38 Billion KRW | 11.75% |
| 2008 | 147.99 Billion KRW | 7.94% |
| 2007 | 137.11 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 72.55 Billion KRW | -6.01% |
| 2024 Q2 | 70.75 Billion KRW | -2.49% |
| 2023 Q4 | 77.19 Billion KRW | 7.48% |
| 2023 FY | 292.12 Billion KRW | 6.6% |
| 2023 Q1 | 70.02 Billion KRW | -6.7% |
| 2023 Q2 | 73.08 Billion KRW | 4.36% |
| 2023 Q3 | 71.82 Billion KRW | -1.72% |
| 2022 FY | 274.03 Billion KRW | 9.58% |
| 2022 Q3 | 70.67 Billion KRW | 4.7% |
| 2022 Q4 | 75.05 Billion KRW | 6.2% |
| 2022 Q1 | 60.8 Billion KRW | 25.29% |
| 2022 Q2 | 67.49 Billion KRW | 11.01% |
| 2021 Q2 | 64.42 Billion KRW | 16.8% |
| 2021 Q4 | 48.52 Billion KRW | -40.79% |
| 2021 Q3 | 81.96 Billion KRW | 27.23% |
| 2021 FY | 250.07 Billion KRW | 6.34% |
| 2021 Q1 | 55.15 Billion KRW | -7.11% |
| 2020 FY | 235.16 Billion KRW | -2.79% |
| 2020 Q1 | 57.71 Billion KRW | -2.43% |
| 2020 Q3 | 56.83 Billion KRW | -7.2% |
| 2020 Q4 | 59.37 Billion KRW | 4.48% |
| 2020 Q2 | 61.24 Billion KRW | 6.11% |
| 2019 Q1 | 60.67 Billion KRW | -5.65% |
| 2019 Q2 | 61.01 Billion KRW | 0.56% |
| 2019 Q4 | 59.15 Billion KRW | -3.17% |
| 2019 FY | 241.92 Billion KRW | -6.96% |
| 2019 Q3 | 61.08 Billion KRW | 0.12% |
| 2018 Q4 | 64.3 Billion KRW | -2.14% |
| 2018 FY | 260.01 Billion KRW | 6.01% |
| 2018 Q3 | 65.71 Billion KRW | 0.21% |
| 2018 Q2 | 65.57 Billion KRW | 1.78% |
| 2018 Q1 | 64.42 Billion KRW | 11.11% |
| 2017 Q1 | 60.06 Billion KRW | 0.09% |
| 2017 Q2 | 62.74 Billion KRW | 4.46% |
| 2017 Q3 | 64.47 Billion KRW | 2.74% |
| 2017 FY | 245.27 Billion KRW | 2.49% |
| 2017 Q4 | 57.98 Billion KRW | -10.06% |
| 2016 Q4 | 60.01 Billion KRW | -1.79% |
| 2016 Q1 | 58.18 Billion KRW | 4.8% |
| 2016 FY | 239.31 Billion KRW | 10.53% |
| 2016 Q2 | 60 Billion KRW | 3.14% |
| 2016 Q3 | 61.1 Billion KRW | 1.83% |
| 2015 Q4 | 55.51 Billion KRW | -0.52% |
| 2015 Q2 | 53.65 Billion KRW | 4.12% |
| 2015 FY | 216.51 Billion KRW | 7.55% |
| 2015 Q3 | 55.8 Billion KRW | 4.01% |
| 2015 Q1 | 51.53 Billion KRW | 2.69% |
| 2014 Q2 | 50.36 Billion KRW | 0.25% |
| 2014 Q1 | 50.24 Billion KRW | 3.54% |
| 2014 FY | 201.3 Billion KRW | 4.84% |
| 2014 Q4 | 50.18 Billion KRW | -0.65% |
| 2014 Q3 | 50.5 Billion KRW | 0.28% |
| 2013 Q3 | 48.91 Billion KRW | 4.45% |
| 2013 FY | 192 Billion KRW | 3.4% |
| 2013 Q2 | 46.82 Billion KRW | -1.9% |
| 2013 Q1 | 47.73 Billion KRW | 3.99% |
| 2013 Q4 | 48.52 Billion KRW | -0.8% |
| 2012 Q1 | 44.5 Billion KRW | -3.62% |
| 2012 Q2 | 45.65 Billion KRW | 2.57% |
| 2012 Q3 | 49.63 Billion KRW | 8.73% |
| 2012 Q4 | 45.9 Billion KRW | -7.52% |
| 2012 FY | 185.7 Billion KRW | -7.96% |
| 2011 Q4 | 46.17 Billion KRW | -10.42% |
| 2011 Q1 | 53.16 Billion KRW | 4.7% |
| 2011 Q2 | 50.86 Billion KRW | -4.33% |
| 2011 FY | 201.75 Billion KRW | 0.67% |
| 2011 Q3 | 51.55 Billion KRW | 1.36% |
| 2010 FY | 200.41 Billion KRW | 21.18% |
| 2010 Q2 | 51.13 Billion KRW | 10.09% |
| 2010 Q3 | 52.04 Billion KRW | 1.78% |
| 2010 Q1 | 46.44 Billion KRW | 9.9% |
| 2010 Q4 | 50.77 Billion KRW | -2.44% |
| 2009 Q3 | 42.86 Billion KRW | 4.05% |
| 2009 Q4 | 42.26 Billion KRW | -1.39% |
| 2009 Q1 | 39.07 Billion KRW | 6.76% |
| 2009 FY | 165.38 Billion KRW | 11.75% |
| 2009 Q2 | 41.19 Billion KRW | 5.43% |
| 2008 Q3 | 38.47 Billion KRW | 9.92% |
| 2008 Q4 | 36.59 Billion KRW | -4.88% |
| 2008 FY | 147.99 Billion KRW | 7.94% |
| 2008 Q1 | 37.92 Billion KRW | 2.69% |
| 2008 Q2 | 35 Billion KRW | -7.7% |
| 2007 Q1 | 30.18 Billion KRW | 0.0% |
| 2007 Q3 | 36.62 Billion KRW | 9.7% |
| 2007 Q2 | 33.38 Billion KRW | 10.61% |
| 2007 FY | 137.11 Billion KRW | 0.0% |
| 2007 Q4 | 36.92 Billion KRW | 0.84% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -112.907% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 74.194% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 54.244% |
| HANDOK Inc. | 522.74 Billion KRW | 44.116% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -115.796% |
| Yuhan Corporation | 1858.98 Billion KRW | 84.286% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 56.003% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -462.272% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 80.406% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -116.536% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 21.161% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -229.74% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -72.279% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -30.149% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -112.907% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -274.268% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -93.371% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -234.382% |
| JW Holdings Corporation | 928.07 Billion KRW | 68.523% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 51.373% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 82.501% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 60.973% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -45.898% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -61.609% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -48.783% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 59.784% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -112.907% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 80.711% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 78.759% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 60.973% |
| Yuhan Corporation | 1858.98 Billion KRW | 84.286% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 63.241% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -24.362% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 50.867% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 60.973% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -4.727% |
| CKD Bio Corp. | 160.35 Billion KRW | -82.179% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 44.563% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 19.102% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -26.795% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -45.898% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 66.795% |
| Boryung Corporation | 859.62 Billion KRW | 66.017% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -131.98% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 21.161% |
| JW Lifescience Corporation | 206.86 Billion KRW | -41.22% |